{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:06:27Z","timestamp":1795086387386,"version":"4.10.2"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T00:00:00Z","timestamp":1704240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970811"],"award-info":[{"award-number":["81970811"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Studies have shown that tet methylcytosine dioxygenase 2 (TET2) is highly expressed in diabetic retinopathy (DR), which reduces the DNA methylation of downstream gene promoters and activates the transcription. Abnormally expressed TET2 and downstream genes in a high-glucose environment are associated with retinal capillary leakage and neovascularization. Here, we investigated the downstream genes of TET2 and its potential association with neovascularization in proliferative diabetic retinopathy (PDR).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>GSE60436, GSE57362, and GSE158333 datasets were analyzed to identify TET2-related hypomethylated and upregulated genes in PDR. Gene expression and promoter methylation of these genes under high glucose treatment were verified. Moreover, TET2 knockdown was used to assess its impact on tube formation and migration in human retinal microvascular endothelial cells (HRMECs), as well as its influence on downstream genes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our analysis identified three key genes (<jats:italic>PARVB<\/jats:italic>, <jats:italic>PTPRE<\/jats:italic>, <jats:italic>ECM1<\/jats:italic>) that were closely associated with TET2 regulation. High glucose-treated HRMECs exhibited increased expression of TET2 and <jats:italic>ECM1<\/jats:italic> while decreasing the promoter methylation level of <jats:italic>ECM1<\/jats:italic>. Subsequently, TET2 knockdown led to decreased migration ability and tube formation function of HRMECs. We further found a decreased expression of <jats:italic>PARVB<\/jats:italic>, <jats:italic>PTPRE<\/jats:italic>, and <jats:italic>ECM1<\/jats:italic>, accompanied by an increase in the promoter methylation of <jats:italic>ECM1<\/jats:italic>.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings indicate the involvement of dysregulated TET2 expression in neovascularization by regulating the promoter methylation and transcription of downstream genes (notably <jats:italic>ECM1<\/jats:italic>), eventually leading to PDR. The TET2-induced hypomethylation of downstream gene promoters represents a potential therapeutic target and offers a novel perspective on the mechanism underlying neovascularization in PDR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical Abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1186\/s13148-023-01619-1","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:02:53Z","timestamp":1704290573000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["TET2-mediated ECM1 hypomethylation promotes the neovascularization in active proliferative diabetic retinopathy"],"prefix":"10.1186","volume":"16","author":[{"given":"Chunyang","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chufeng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunren","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongwei","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,3]]},"reference":[{"key":"1619_CR1","doi-asserted-by":"publisher","first-page":"1077669","DOI":"10.3389\/fendo.2022.1077669","volume":"13","author":"TE Tan","year":"2022","unstructured":"Tan TE, Wong TY. Diabetic retinopathy: Looking forward to 2030. Front Endocrinol (Lausanne). 2022;13:1077669.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1619_CR2","doi-asserted-by":"publisher","first-page":"1055087","DOI":"10.3389\/fimmu.2022.1055087","volume":"13","author":"T Yue","year":"2022","unstructured":"Yue T, et al. The role of inflammation in immune system of diabetic retinopathy: molecular mechanisms, pathogenetic role and therapeutic implications. Front Immunol. 2022;13:1055087.","journal-title":"Front Immunol"},{"issue":"4","key":"1619_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S2213-8587(19)30411-5","volume":"8","author":"S Vujosevic","year":"2020","unstructured":"Vujosevic S, et al. Screening for diabetic retinopathy: new perspectives and challenges. Lancet Diabetes Endocrinol. 2020;8(4):337\u201347.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"1619_CR4","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.3390\/ijms19061816","volume":"19","author":"W Wang","year":"2018","unstructured":"Wang W, Lo ACY. Diabetic retinopathy: pathophysiology and treatments. Int J Mol Sci. 2018;19(6):1816.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"1619_CR5","doi-asserted-by":"publisher","first-page":"7839","DOI":"10.1002\/jcp.27844","volume":"234","author":"R Shafabakhsh","year":"2019","unstructured":"Shafabakhsh R, et al. Role of histone modification and DNA methylation in signaling pathways involved in diabetic retinopathy. J Cell Physiol. 2019;234(6):7839\u201346.","journal-title":"J Cell Physiol"},{"issue":"3","key":"1619_CR6","doi-asserted-by":"publisher","first-page":"624","DOI":"10.3390\/cells9030624","volume":"9","author":"V Const\u00e2ncio","year":"2020","unstructured":"Const\u00e2ncio V, et al. DNA methylation-based testing in liquid biopsies as detection and prognostic biomarkers for the four major cancer types. Cells. 2020;9(3):624.","journal-title":"Cells"},{"issue":"11","key":"1619_CR7","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.tig.2021.05.002","volume":"37","author":"A Nishiyama","year":"2021","unstructured":"Nishiyama A, Nakanishi M. Navigating the DNA methylation landscape of cancer. Trends Genet. 2021;37(11):1012\u201327.","journal-title":"Trends Genet"},{"issue":"9","key":"1619_CR8","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1128\/MCB.22.9.3157-3173.2002","volume":"22","author":"M Curradi","year":"2002","unstructured":"Curradi M, et al. Molecular mechanisms of gene silencing mediated by DNA methylation. Mol Cell Biol. 2002;22(9):3157\u201373.","journal-title":"Mol Cell Biol"},{"issue":"21","key":"1619_CR9","doi-asserted-by":"publisher","first-page":"11652","DOI":"10.3390\/ijms222111652","volume":"22","author":"GA Raciti","year":"2021","unstructured":"Raciti GA, et al. DNA methylation and type 2 diabetes: novel biomarkers for risk assessment? Int J Mol Sci. 2021;22(21):11652.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"1619_CR10","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/clinchem\/hvab204","volume":"68","author":"J Ren","year":"2022","unstructured":"Ren J, et al. Genome-scale methylation analysis of circulating cell-free DNA in gastric cancer patients. Clin Chem. 2022;68(2):354\u201364.","journal-title":"Clin Chem"},{"issue":"7","key":"1619_CR11","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.4103\/1673-5374.361536","volume":"18","author":"DD Liu","year":"2023","unstructured":"Liu DD, et al. Epigenetic modifications and metabolic memory in diabetic retinopathy: beyond the surface. Neural Regen Res. 2023;18(7):1441\u20139.","journal-title":"Neural Regen Res"},{"issue":"1","key":"1619_CR12","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s13578-022-00927-y","volume":"12","author":"C Cai","year":"2022","unstructured":"Cai C, et al. DNA methylation in diabetic retinopathy: pathogenetic role and potential therapeutic targets. Cell Biosci. 2022;12(1):186.","journal-title":"Cell Biosci"},{"issue":"10","key":"1619_CR13","doi-asserted-by":"publisher","first-page":"895","DOI":"10.52586\/4996","volume":"26","author":"C Ma","year":"2021","unstructured":"Ma C, et al. Ten-eleven translocation proteins (TETs): tumor suppressors or tumor enhancers? Front Biosci (Landmark Ed). 2021;26(10):895\u2013915.","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"2","key":"1619_CR14","doi-asserted-by":"publisher","first-page":"10766","DOI":"10.1080\/21655979.2021.2003924","volume":"12","author":"X Liu","year":"2021","unstructured":"Liu X, Cui H. The palliative effects of folic acid on retinal microvessels in diabetic retinopathy via regulating the metabolism of DNA methylation and hydroxymethylation. Bioengineered. 2021;12(2):10766\u201374.","journal-title":"Bioengineered"},{"issue":"12","key":"1619_CR15","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1167\/iovs.18-24548","volume":"59","author":"AJ Duraisamy","year":"2018","unstructured":"Duraisamy AJ, et al. Epigenetics and regulation of oxidative stress in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2018;59(12):4831\u201340.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"1619_CR16","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1021\/acscatal.2c00024","volume":"12","author":"SO Waheed","year":"2022","unstructured":"Waheed SO, et al. How human TET2 enzyme catalyzes the oxidation of unnatural cytosine modifications in double-stranded DNA. ACS Catal. 2022;12(9):5327\u201344.","journal-title":"ACS Catal"},{"issue":"4","key":"1619_CR17","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1080\/15592294.2021.1917152","volume":"17","author":"M De Dieuleveult","year":"2022","unstructured":"De Dieuleveult M, et al. The chromatin remodelling protein LSH\/HELLS regulates the amount and distribution of DNA hydroxymethylation in the genome. Epigenetics. 2022;17(4):422\u201343.","journal-title":"Epigenetics"},{"issue":"1","key":"1619_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13072-018-0174-4","volume":"11","author":"S Rao","year":"2018","unstructured":"Rao S, et al. Systematic prediction of DNA shape changes due to CpG methylation explains epigenetic effects on protein-DNA binding. Epigenetics Chromatin. 2018;11(1):6.","journal-title":"Epigenetics Chromatin"},{"issue":"1","key":"1619_CR19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12967-023-04310-4","volume":"21","author":"L Zhao","year":"2023","unstructured":"Zhao L, et al. The role of TET2-mediated ROBO4 hypomethylation in the development of diabetic retinopathy. J Transl Med. 2023;21(1):455.","journal-title":"J Transl Med"},{"key":"1619_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.896511","volume":"13","author":"X Wang","year":"2022","unstructured":"Wang X, et al. Genomic DNA methylation in diabetic chronic complications in patients with type 2 diabetes mellitus. Front Endocrinol (Lausanne). 2022;13: 896511.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"10","key":"1619_CR21","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/labinvest.2016.78","volume":"96","author":"RA Kowluru","year":"2016","unstructured":"Kowluru RA, Shan Y, Mishra M. Dynamic DNA methylation of matrix metalloproteinase-9 in the development of diabetic retinopathy. Lab Invest. 2016;96(10):1040\u20139.","journal-title":"Lab Invest"},{"issue":"2","key":"1619_CR22","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1167\/iovs.14-15589","volume":"56","author":"K Ishikawa","year":"2015","unstructured":"Ishikawa K, et al. Microarray analysis of gene expression in fibrovascular membranes excised from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 2015;56(2):932\u201346.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1619_CR23","doi-asserted-by":"publisher","first-page":"11762","DOI":"10.1038\/s41598-017-12084-1","volume":"7","author":"M Berdasco","year":"2017","unstructured":"Berdasco M, et al. DNA methylomes reveal biological networks involved in human eye development, functions and associated disorders. Sci Rep. 2017;7(1):11762.","journal-title":"Sci Rep"},{"issue":"4","key":"1619_CR24","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.molcel.2020.11.045","volume":"81","author":"BA Caldwell","year":"2021","unstructured":"Caldwell BA, et al. Functionally distinct roles for TET-oxidized 5-methylcytosine bases in somatic reprogramming to pluripotency. Mol Cell. 2021;81(4):859-869.e8.","journal-title":"Mol Cell"},{"issue":"13","key":"1619_CR25","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1167\/iovs.19-27825","volume":"60","author":"C Gu","year":"2019","unstructured":"Gu C, et al. miR-590-3p inhibits pyroptosis in diabetic retinopathy by targeting NLRP1 and inactivating the NOX4 signaling pathway. Invest Ophthalmol Vis Sci. 2019;60(13):4215\u201323.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"1619_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102460","volume":"56","author":"K Liu","year":"2022","unstructured":"Liu K, et al. Capsaicin ameliorates diabetic retinopathy by inhibiting poldip2-induced oxidative stress. Redox Biol. 2022;56: 102460.","journal-title":"Redox Biol"},{"key":"1619_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.gene.2019.02.040","volume":"698","author":"X Zhong","year":"2019","unstructured":"Zhong X, et al. The expression of TET3 regulated cell proliferation in HepG2 cells. Gene. 2019;698:113\u20139.","journal-title":"Gene"},{"key":"1619_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.743224","volume":"10","author":"A Karmakar","year":"2022","unstructured":"Karmakar A, et al. Identification of epigenetically modified hub genes and altered pathways associated with retinoblastoma. Front Cell Dev Biol. 2022;10: 743224.","journal-title":"Front Cell Dev Biol"},{"key":"1619_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.789923","volume":"8","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, et al. Validated impacts of N6-methyladenosine methylated mRNAs on apoptosis and angiogenesis in myocardial infarction based on MeRIP-seq analysis. Front Mol Biosci. 2021;8: 789923.","journal-title":"Front Mol Biosci"},{"issue":"2","key":"1619_CR30","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/jcmm.14010","volume":"23","author":"Y Si","year":"2019","unstructured":"Si Y, et al. Fisetin decreases TET1 activity and CCNY\/CDK16 promoter 5hmC levels to inhibit the proliferation and invasion of renal cancer stem cell. J Cell Mol Med. 2019;23(2):1095\u2013105.","journal-title":"J Cell Mol Med"},{"issue":"3","key":"1619_CR31","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1177\/0271678X20912965","volume":"41","author":"KC Morris-Blanco","year":"2021","unstructured":"Morris-Blanco KC, et al. TET3 regulates DNA hydroxymethylation of neuroprotective genes following focal ischemia. J Cereb Blood Flow Metab. 2021;41(3):590\u2013603.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"1619_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12935-023-03021-6","volume":"23","author":"L Yang","year":"2023","unstructured":"Yang L, et al. The novel oncogenic factor TET3 combines with AHR to promote thyroid cancer lymphangiogenesis via the HIF-1\u03b1\/VEGF signaling pathway. Cancer Cell Int. 2023;23(1):206.","journal-title":"Cancer Cell Int"},{"issue":"6","key":"1619_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1167\/tvst.8.6.43","volume":"8","author":"AJ Duraisamy","year":"2019","unstructured":"Duraisamy AJ, et al. Epigenetic modifications in peripheral blood as potential noninvasive biomarker of diabetic retinopathy. Transl Vis Sci Technol. 2019;8(6):43.","journal-title":"Transl Vis Sci Technol"},{"key":"1619_CR34","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12916-015-0421-5","volume":"13","author":"E Agardh","year":"2015","unstructured":"Agardh E, et al. Genome-wide analysis of DNA methylation in subjects with type 1 diabetes identifies epigenetic modifications associated with proliferative diabetic retinopathy. BMC Med. 2015;13:182.","journal-title":"BMC Med"},{"issue":"5","key":"1619_CR35","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1111\/ced.12783","volume":"41","author":"X Niu","year":"2016","unstructured":"Niu X, et al. mRNA and protein expression of the angiogenesis-related genes EDIL3, AMOT and ECM1 in mesenchymal stem cells in psoriatic dermis. Clin Exp Dermatol. 2016;41(5):533\u201340.","journal-title":"Clin Exp Dermatol"},{"key":"1619_CR36","doi-asserted-by":"publisher","first-page":"1005915","DOI":"10.3389\/fphar.2022.1005915","volume":"13","author":"S Long","year":"2022","unstructured":"Long S, et al. ECM1 regulates the resistance of colorectal cancer to 5-FU treatment by modulating apoptotic cell death and epithelial-mesenchymal transition induction. Front Pharmacol. 2022;13:1005915.","journal-title":"Front Pharmacol"},{"issue":"7","key":"1619_CR37","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1038\/s41374-020-0415-6","volume":"100","author":"SS Steinhaeuser","year":"2020","unstructured":"Steinhaeuser SS, et al. ECM1 secreted by HER2-overexpressing breast cancer cells promotes formation of a vascular niche accelerating cancer cell migration and invasion. Lab Invest. 2020;100(7):928\u201344.","journal-title":"Lab Invest"},{"issue":"12","key":"1619_CR38","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/s13059-014-0533-9","volume":"15","author":"F Gao","year":"2014","unstructured":"Gao F, et al. Integrated analyses of DNA methylation and hydroxymethylation reveal tumor suppressive roles of ECM1, ATF5, and EOMES in human hepatocellular carcinoma. Genome Biol. 2014;15(12):533.","journal-title":"Genome Biol"},{"key":"1619_CR39","volume":"26","author":"S Zhang","year":"2021","unstructured":"Zhang S, et al. Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently. Biochem Biophys Rep. 2021;26: 100974.","journal-title":"Biochem Biophys Rep"},{"issue":"1","key":"1619_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.7150\/jca.27633","volume":"10","author":"J Liang","year":"2019","unstructured":"Liang J, et al. Tuning the protein phosphorylation by receptor type protein tyrosine phosphatase epsilon (PTPRE) in normal and cancer cells. J Cancer. 2019;10(1):105\u201311.","journal-title":"J Cancer"},{"issue":"1","key":"1619_CR41","doi-asserted-by":"publisher","first-page":"H396","DOI":"10.1152\/ajpheart.2001.281.1.H396","volume":"281","author":"LJ Thompson","year":"2001","unstructured":"Thompson LJ, et al. PTP-epsilon, a tyrosine phosphatase expressed in endothelium, negatively regulates endothelial cell proliferation. Am J Physiol Heart Circ Physiol. 2001;281(1):H396-403.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"1619_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.mce.2018.01.020","volume":"473","author":"P Kober","year":"2018","unstructured":"Kober P, et al. DNA methylation profiling in nonfunctioning pituitary adenomas. Mol Cell Endocrinol. 2018;473:194\u2013204.","journal-title":"Mol Cell Endocrinol"},{"key":"1619_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.705547","volume":"11","author":"W Yu","year":"2021","unstructured":"Yu W, et al. Construction of novel methylation-driven gene model and investigation of PARVB function in glioblastoma. Front Oncol. 2021;11: 705547.","journal-title":"Front Oncol"},{"issue":"2","key":"1619_CR44","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.jhep.2015.02.049","volume":"63","author":"T Kitamoto","year":"2015","unstructured":"Kitamoto T, et al. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3, SAMM50, and PARVB of patients with non-alcoholic fatty liver disease. J Hepatol. 2015;63(2):494\u2013502.","journal-title":"J Hepatol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01619-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T14:03:43Z","timestamp":1704290623000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01619-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1619"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01619-1","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,3]]},"assertion":[{"value":"9 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The manuscript is approved by all authors for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"6"}}